AZN:NYE-Astrazeneca PLC

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 34.99

Change

-0.66 (-1.85)%

Market Cap

USD 88.61B

Volume

4.76M

Yahoo Analyst Target

USD 39.45 (12.75%)

STA Analyst Target

USD 36.17 (3.36%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B

ETFs Containing AZN

PPH VanEck Vectors Pharmaceut.. 5.11 % 0.35 %

-0.10 (-0.46%)

USD 0.30B
HHL:CA Healthcare Leaders Income.. 5.05 % 1.37 %

-0.04 (-0.46%)

CAD 0.26B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.84% 13% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.84% 13% F 43% F
Trailing 12 Months  
Capital Gain 22.43% 70% C- 74% C
Dividend Return 4.79% 94% A 65% D
Total Return 27.22% 70% C- 77% C+
Trailing 5 Years  
Capital Gain 44.20% 50% F 64% D
Dividend Return 28.52% 93% A 79% C+
Total Return 72.72% 56% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 7.82% 52% F 67% D+
Dividend Return 12.35% 70% C- 74% C
Total Return 4.53% 94% A 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 22.23% 48% F 31% F
Risk Adjusted Return 55.54% 65% D 51% F
Market Capitalization 65.58B 55% F 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.10 70% C- 49% F
Price/Book Ratio 2.61 65% D 39% F
Price / Cash Flow Ratio 1.91 83% B 66% D
Price/Free Cash Flow Ratio 81.37 9% F 6% F
Management Effectiveness  
Return on Equity 16.48% 61% D- 77% C+
Return on Invested Capital 11.58% 61% D- 67% D+
Return on Assets 3.91% 48% F 63% D
Debt to Equity Ratio 114.25% 36% F 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.